GVHD therapy with ruxolitinib is frequently associated with cytopenias, but significant decline in hemoglobin level was only observed in non-responders at day 28 Meeting Abstract
| Authors: | Gergoudis, S.; Devlin, S. M.; Susman, P.; Singh, A.; Chinapen, S.; Perales, M. A.; Ponce, D. M. |
| Abstract Title: | GVHD therapy with ruxolitinib is frequently associated with cytopenias, but significant decline in hemoglobin level was only observed in non-responders at day 28 |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 7349 |
| End Page: | 7350 |
| Language: | English |
| ACCESSION: | WOS:001415922300016 |
| DOI: | 10.1182/blood-2024-210081 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
